10112- ET-10 EVALUATING PBC-IP AS A NOVEL BORON CARRIER IN BNCT
Shinji Kawabata, Hiroyuki Nakamura, Kohei Tsujino, Kenichiro Eza, Rina Kazuki, Yoshiki Fujikawa, Hideki Kashiwagi, Naosuke Nonoguchi, Motomasa Furuse, Toshihiro Takami, Masahiko Wanibuchi · 2024
Read 10112- ET-10 EVALUATING PBC-IP AS A NOVEL BORON CARRIER IN BNCT by Shinji Kawabata, Hiroyuki Nakamura, Kohei Tsujino, Kenichiro Eza, Rina Kazuki, Yoshiki Fujikawa, Hideki Kashiwagi, Naosuke Nonoguchi, Motomasa Furuse, Toshihiro Takami, Masahiko Wanibuchi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605630.txt.
Description
Boron neutron capture therapy kills tumors from inside, but only if a boron carrier reaches cancers that ignore the standard one. Shinji Kawabata and ten co-authors report in 2024 on PBC-IP, a carrier aimed at folate receptors. It was delivered straight into rat brain tumors by a pumped catheter. Half the treated rats lived past ninety days, far beyond the standard carrier's thirty-seven.
The report is really a roadmap. The team walks the nonclinical path toward a human trial, from quality and safety testing in rats and dogs to catheter placement studies and talks with regulators. Academic drug discovery, they note, rarely plans this road early. Their account aims to show clinician scientists how the approval journey is built.
Catalog record
| CREATOR | Shinji Kawabata, Hiroyuki Nakamura, Kohei Tsujino, Kenichiro Eza, Rina Kazuki, Yoshiki Fujikawa, Hideki Kashiwagi, Naosuke Nonoguchi, Motomasa Furuse, Toshihiro Takami, Masahiko Wanibuchi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |